Finding the needle in the haystack: systematic identification of psychobiotics
The brain–gut–microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria, which when ingested in adequate amounts, confer mental health benefits, are in...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2018-12, Vol.175 (24), p.4430-4438 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4438 |
|---|---|
| container_issue | 24 |
| container_start_page | 4430 |
| container_title | British journal of pharmacology |
| container_volume | 175 |
| creator | Bambury, Aisling Sandhu, Kiran Cryan, John F Dinan, Timothy G |
| description | The brain–gut–microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria, which when ingested in adequate amounts, confer mental health benefits, are increasingly of interest, as preclinical trials continue to show promising results. Particularly in stress‐related, anxiety and depressive disorders, there is potential for psychobiotics to deliver new therapies. The question of which microbes may prove to be the most promising psychobiotic in delivering such therapies at a clinical level is of great importance. Here we look at the characteristics of psychobiotics, in an attempt to present an outline from which the identification of potential new psychobiotics may be possible.
Linked Articles
This article is part of a themed section on When Pharmacology Meets the Microbiome: New Targets for Therapeutics? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.24/issuetoc |
| doi_str_mv | 10.1111/bph.14127 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6255950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1977784209</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4817-5771de955b217d32ca48d92990e6265215b53be3a50be62f4d703bc399e97cdc3</originalsourceid><addsrcrecordid>eNp1kD9PwzAQxS0EglIY-AIoIwwB_4njmAEJEAUkBAwwW459IYYkLnEK6rfHtAXBwC2-8_vp3ekhtEfwEYl1XE7rI5IRKtbQiGQiTzkryDoaYYxFSkhRbKHtEF4wjqLgm2iLSpoxytgI3U1cZ133nAw1JB2AbSBx3WKq9TwM2ryeJCE20OrBmcRZ6AZXORMn3yW-SqZhbmpfOh_lsIM2Kt0E2F29Y_Q0uXy8uE5v769uLs5uU5MVRKRcCGJBcl5SIiyjRmeFlVRKDDnNOSW85KwEpjku40-VWYFZaZiUIIWxho3R6dJ3OitbsCYe1etGTXvX6n6uvHbqr9K5Wj37d5VTziXH0eBgZdD7txmEQbUuGGga3YGfBUWkEKLIKJYRPVyipvch9FD9rCFYfeWvYv5qkX9k93_f9UN-Bx6B4yXw4RqY_--kzh-ul5afQYyQXw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1977784209</pqid></control><display><type>article</type><title>Finding the needle in the haystack: systematic identification of psychobiotics</title><source>Wiley-Blackwell Journals</source><source>Wiley-Blackwell Open Access Backfiles</source><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Bambury, Aisling ; Sandhu, Kiran ; Cryan, John F ; Dinan, Timothy G</creator><creatorcontrib>Bambury, Aisling ; Sandhu, Kiran ; Cryan, John F ; Dinan, Timothy G</creatorcontrib><description>The brain–gut–microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria, which when ingested in adequate amounts, confer mental health benefits, are increasingly of interest, as preclinical trials continue to show promising results. Particularly in stress‐related, anxiety and depressive disorders, there is potential for psychobiotics to deliver new therapies. The question of which microbes may prove to be the most promising psychobiotic in delivering such therapies at a clinical level is of great importance. Here we look at the characteristics of psychobiotics, in an attempt to present an outline from which the identification of potential new psychobiotics may be possible.
Linked Articles
This article is part of a themed section on When Pharmacology Meets the Microbiome: New Targets for Therapeutics? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.24/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.14127</identifier><identifier>PMID: 29243233</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Animals ; Gastrointestinal Microbiome - physiology ; Humans ; Mental Disorders - microbiology ; Mental Disorders - therapy ; Probiotics - analysis ; Probiotics - therapeutic use ; Review ; Themed Section: Review</subject><ispartof>British journal of pharmacology, 2018-12, Vol.175 (24), p.4430-4438</ispartof><rights>2017 The British Pharmacological Society</rights><rights>2017 The British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4817-5771de955b217d32ca48d92990e6265215b53be3a50be62f4d703bc399e97cdc3</citedby><cites>FETCH-LOGICAL-c4817-5771de955b217d32ca48d92990e6265215b53be3a50be62f4d703bc399e97cdc3</cites><orcidid>0000-0002-2316-7220</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255950/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255950/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1416,1432,27923,27924,45573,45574,46408,46832,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29243233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bambury, Aisling</creatorcontrib><creatorcontrib>Sandhu, Kiran</creatorcontrib><creatorcontrib>Cryan, John F</creatorcontrib><creatorcontrib>Dinan, Timothy G</creatorcontrib><title>Finding the needle in the haystack: systematic identification of psychobiotics</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>The brain–gut–microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria, which when ingested in adequate amounts, confer mental health benefits, are increasingly of interest, as preclinical trials continue to show promising results. Particularly in stress‐related, anxiety and depressive disorders, there is potential for psychobiotics to deliver new therapies. The question of which microbes may prove to be the most promising psychobiotic in delivering such therapies at a clinical level is of great importance. Here we look at the characteristics of psychobiotics, in an attempt to present an outline from which the identification of potential new psychobiotics may be possible.
Linked Articles
This article is part of a themed section on When Pharmacology Meets the Microbiome: New Targets for Therapeutics? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.24/issuetoc</description><subject>Animals</subject><subject>Gastrointestinal Microbiome - physiology</subject><subject>Humans</subject><subject>Mental Disorders - microbiology</subject><subject>Mental Disorders - therapy</subject><subject>Probiotics - analysis</subject><subject>Probiotics - therapeutic use</subject><subject>Review</subject><subject>Themed Section: Review</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD9PwzAQxS0EglIY-AIoIwwB_4njmAEJEAUkBAwwW459IYYkLnEK6rfHtAXBwC2-8_vp3ekhtEfwEYl1XE7rI5IRKtbQiGQiTzkryDoaYYxFSkhRbKHtEF4wjqLgm2iLSpoxytgI3U1cZ133nAw1JB2AbSBx3WKq9TwM2ryeJCE20OrBmcRZ6AZXORMn3yW-SqZhbmpfOh_lsIM2Kt0E2F29Y_Q0uXy8uE5v769uLs5uU5MVRKRcCGJBcl5SIiyjRmeFlVRKDDnNOSW85KwEpjku40-VWYFZaZiUIIWxho3R6dJ3OitbsCYe1etGTXvX6n6uvHbqr9K5Wj37d5VTziXH0eBgZdD7txmEQbUuGGga3YGfBUWkEKLIKJYRPVyipvch9FD9rCFYfeWvYv5qkX9k93_f9UN-Bx6B4yXw4RqY_--kzh-ul5afQYyQXw</recordid><startdate>201812</startdate><enddate>201812</enddate><creator>Bambury, Aisling</creator><creator>Sandhu, Kiran</creator><creator>Cryan, John F</creator><creator>Dinan, Timothy G</creator><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2316-7220</orcidid></search><sort><creationdate>201812</creationdate><title>Finding the needle in the haystack: systematic identification of psychobiotics</title><author>Bambury, Aisling ; Sandhu, Kiran ; Cryan, John F ; Dinan, Timothy G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4817-5771de955b217d32ca48d92990e6265215b53be3a50be62f4d703bc399e97cdc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Gastrointestinal Microbiome - physiology</topic><topic>Humans</topic><topic>Mental Disorders - microbiology</topic><topic>Mental Disorders - therapy</topic><topic>Probiotics - analysis</topic><topic>Probiotics - therapeutic use</topic><topic>Review</topic><topic>Themed Section: Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bambury, Aisling</creatorcontrib><creatorcontrib>Sandhu, Kiran</creatorcontrib><creatorcontrib>Cryan, John F</creatorcontrib><creatorcontrib>Dinan, Timothy G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bambury, Aisling</au><au>Sandhu, Kiran</au><au>Cryan, John F</au><au>Dinan, Timothy G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Finding the needle in the haystack: systematic identification of psychobiotics</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2018-12</date><risdate>2018</risdate><volume>175</volume><issue>24</issue><spage>4430</spage><epage>4438</epage><pages>4430-4438</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>The brain–gut–microbiota axis is increasingly viewed as a novel paradigm in neuroscience with the capacity to generate innovative therapies for patients with psychiatric illnesses. Psychobiotics, defined as live bacteria, which when ingested in adequate amounts, confer mental health benefits, are increasingly of interest, as preclinical trials continue to show promising results. Particularly in stress‐related, anxiety and depressive disorders, there is potential for psychobiotics to deliver new therapies. The question of which microbes may prove to be the most promising psychobiotic in delivering such therapies at a clinical level is of great importance. Here we look at the characteristics of psychobiotics, in an attempt to present an outline from which the identification of potential new psychobiotics may be possible.
Linked Articles
This article is part of a themed section on When Pharmacology Meets the Microbiome: New Targets for Therapeutics? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.24/issuetoc</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>29243233</pmid><doi>10.1111/bph.14127</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2316-7220</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2018-12, Vol.175 (24), p.4430-4438 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6255950 |
| source | Wiley-Blackwell Journals; Wiley-Blackwell Open Access Backfiles; MEDLINE; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Animals Gastrointestinal Microbiome - physiology Humans Mental Disorders - microbiology Mental Disorders - therapy Probiotics - analysis Probiotics - therapeutic use Review Themed Section: Review |
| title | Finding the needle in the haystack: systematic identification of psychobiotics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A51%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Finding%20the%20needle%20in%20the%20haystack:%20systematic%20identification%20of%20psychobiotics&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Bambury,%20Aisling&rft.date=2018-12&rft.volume=175&rft.issue=24&rft.spage=4430&rft.epage=4438&rft.pages=4430-4438&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.14127&rft_dat=%3Cproquest_pubme%3E1977784209%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1977784209&rft_id=info:pmid/29243233&rfr_iscdi=true |